Clinical Trial Calendar

Results Date
Company Name
Q2 2020
Myovant Sciences Ltd
Data from 2nd phase III trial of Relugolix (SPIRIT 2)
Endometriosis-associated pain in Women
Q2 2020
Final results from phase III study of SGX942 (dusquetide)
Oral mucositis in patients with head and neck cancer
Q2 2020
Catabasis Pharmaceuticals, Inc.
Top-line results from phase III trial of Edasalonexent (POLARIS DMD)
Duchenne muscular dystrophy
Q2 2020
Akebia Therapeutics, Inc.
Top-line data from Two global phase III studies of Vadadustat ( INNO2VATE)
Dialysis-dependent chronic kidney disease (CKD) subjects with anemia due to CKD
Q2 2020
IDEAYA Biosciences
Interim data from phase I/II basket trial of IDE196
Ssolid tumors harboring GNAQ/11 mutations or PRKC fusions
Q2 2020
Blueprint Medicines
Top-line from phase III VOYAGER trial
Fourth-line gastrointestinal stromal tumors (GIST)
Q2 2020
Momenta Pharmaceuticals Inc
Top-line data from Phase 2 trial of Nipocalimab (Vivacity-MG)
Myasthenia gravis
Q2 2020
Foamix Pharmaceuticals Ltd.
Topline data from phase II trial of FCD105
moderate-to-severe acne vulgaris.
Q2 2020
ObsEva SA
6-month primary endpoint data from phase III clinical trial of Linzagolix (PRIMROSE1)
Heavy menstrual bleeding due to uterine fibroids
Q2 2020
Akero Therapeutics Inc.
Full data readout from phase IIa study of AKR-001 (BALANCED)
Non-alcoholic steatohepatitis
Q2 2020
Oncolytics Biotech
Final data from phase Ib window of opportunity study assessing Pelareorep with or without Roche's Tecentriq (AWARE-1)
breast cancer
Feb 2020
CTD Holdings Inc
Data from Phase I trial of Trappsol
Niemann-Pick Disease Type C
Verona Pharma plc
Results from phase IIb trial of nebulized Ensifentrine as an add-on to inhaled tiotropium
Chronic obstructive pulmonary disease
Applied Genetic Technologies Corp.
Interim 6-month data from expansion group of a phase I/II study of gene therapy
X-linked Retinitis Pigmentosa
Jan 2020
Applied Genetic Technologies Corp.
Interim six-month data from parallel phase I/II studies of gene therapy(CNGB3 trial)
Jan 2020
Applied Genetic Technologies Corp.
Interim six-month data from parallel phase I/II studies of gene therapy(CNGA3 trial)
Q1 2020
Oramed Pharmaceuticals Inc.
Read-out of data from a second cohort of phase IIb trial of ORMD-0801
Type 2 diabetes
after Q1 2020
Krystal Biotech, Inc.
Interim results from phase I/II study of KB105 (GEM-3)
Transglutaminase-1 (TGM1) deficient autosomal recessive congenital ichthyosis (ARCI)
Q1 2020
Axsome Therapeutics, Inc.
Topline data from a phase III trial of AXS-07 ( INTERCEPT)
Q1 2020
Kadmon Holdings LLC
Data from primary analysis of open-label registration trial of KD025 (KD025-213)
Chronic graft-versus-host disease (cGVHD) who have received at least two prior lines of systemic therapy
Q1 2020
Caladrius Biosciences, Inc.
Full results from phase II trial of CLBS16 (ESCaPE-CMD)
Coronary microvascular dysfunction
Q1 2020
Tonix Pharmaceuticals Holding Corp.
Results from added interim analysis of phase III trial of Tonmya (RECOVERY)
Posttraumatic stress disorder,
Precision BioSciences Inc
Initial data from Phase 1/2a clinical trial of PBCAR20A
NHL, chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL)
Early Q1 2020
Biohaven Pharmaceutical Holding Co Ltd.
Topline data from pivotal phase III clinical trial of Troriluzole
General Anxiety Disorder
after Q1 2020
RAPT Therapeutics, Inc.
Results from phase II portion of phase I/II trial of FLX475 as a monotherapy and in combination with Merck's Keytruda
charged tumors